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Article Outline

1. Introduction
Tissues of the central nervous system, including the brain and retina, depend on intact
blood–brain and blood–retinal barriers (BRB), respectively, to partition them from the
systemic circulation (reviewed in Takata et al., 1997). The BRB consists of the
innerBRB (iBRB) and the outerBRB (oBRB) with the endothelial membranes of the
retinal vessels forming the iBRB while the retinal pigment epithelial cells and Bruchs
membrane are the main structures involved in forming the oBRB. Breakdown of the
inner blood retinal barrier (iBRB) is a major cause of visual loss in a number of
human ocular disorders including diabetic retinopathy, sickle-cell disease and cystoid
macular edema (Vinores et al., 1999, Vinores et al., 1995, Dorchy, 1993, Carney et
al., 1986 and Barber, A.J). The endothelial cells of the iBRB are joined by highly
specialised tight junctional complexes that, in part, confer highly selective properties
to these vessels (Takata et al., 1997). Tight junctions make a seal around the
circumference of cells and function as barriers preventing free diffusion of solutes
through the paracellular pathway. Occludin and ZO-1 are key tight junction proteins.
At the tight junction ZO-1 binds to the actin cytoskeleton through its carboxyl
terminal end, and forms a bridge between the C-terminal sequences of occludin and βactin.
The configuration of several tight junction proteins, including occludin and zonula
occludens (ZO-1, -2 and -3), can be altered by selective phosphorylation of key
components to modulate barrier integrity (Gonzalez-Mariscal et al., 2003). Increased
expression of occludin has been found to correlate with improved barrier function
(reviewed in Harhaj and Antonetti, 2004) and modulation of occludin phosphorylation
regulates its cellular localisation (Wong, 1997).
Phosphorylation of ZO-1 may affect barrier properties, for instance ZO-1 tyrosine
phosphorylation has been correlated with formation of tight junctions in glomeruli
(Kurihara et al., 1995) and ZO-1 may also be regulated by serine and/or threonine
phosphorylation (Balda et al., 1996).
The vasoactive growth factor vascular endothelial growth factor (VEGF) has been
shown to affect tight junction integrity at the plasma membrane with rapid
phosphorylation of the tight junction proteins occludin and ZO-1 and this has
important consequences for iBRB function. VEGF induced changes in tight junction
phosphorylation may serve as a mechanism by which VEGF has the capacity to
regulate endothelial permeability (Antonetti et al., 1999). VEGF increases the
permeability of the microvasculature. The permeability increase is associated with
altered tight junction organisation (Barber and Antonetti, 2003). The signal
transduction pathway and molecular targets responsible for the VEGF mediated
increases in permeability are still being elucidated, whilst it has been shown that
phosphorylation of occludin is linked with increases in permeability (Antonetti et al.,
1999). VEGF activates phosphatidylinositol 3-kinase which may lead to activation of
atypical PKC isoforms (Toker and Cantley, 1997).

Endostatin is a 20 kDa fragment of collagen XVIII, derived by selective proteolytic
degradation of vascular basement membranes (Halfter et al., 1998). This peptide can
prevent tumour angiogenesis (O'Reilly et al., 1997) and has also been shown to be
efficacious in the eye by preventing retinal and choroidal neovascularisation (Mori et
al., 2001, Auricchio et al., 2002 and Le Gat et al., 2003). Endostatin may also prevent
vasopermeability responses by growth factors and recent studies have suggested that
endostatin can reduce VEGF-induced retinal vascular permeability in double
transgenic mice with inducible expression of VEGF165 in the retina (Takahashi et al.,
2003). VEGF-induced permeability was assessed via [3H] mannitol permeation,
fluorescein angiography and assessment of edema was conducted by measurement of
retinal thickness. These recent studies reported mice, when given sub-retinal
injections of a bovine immunodeficiency viral vector expressing endostatin, showed a
marked decrease in retinal vascular permeability, neovascularisation and retinal
detachment (Takahashi et al., 2003). However, exact concentrations of endostatin
required to decrease the VEGF induced permeability and effects on tight junction
expression were not elucidated.
In the current study, we hypothesise that VEGF165-induced leakage from the retinal
microvascular endothelium may be modulated by controlled concentrations of
endostatin. We present evidence herein that endostatin affects VEGF-mediated
permeability across monolayers of RMEC's in vitro via regulation of tight junction
integrity, and significantly decreases VEGF-mediated retinal vaso-permeability in
vivo.

2. Methods
2.1. Cell Culture
Primary retinal microvascular endothelial cells (RMECs) were isolated from bovine
retinas as described previously (Stitt et al., 2000) and used at between passage
numbers 3–5. The cells were propagated in growth medium (DMEM) containing 10%
porcine serum until they formed confluent monolayers. Six hours prior to growth
factor treatment, RMECs were stepped down from 10 to 2% porcine serum.
Recombinant human VEGF165 (Sigma Aldrich, Ireland) was added to give a final
concentration of 10 or 100 ng ml−1. Recombinant human endostatin (Calbiochem,
Darmstadt, Germany) was added to give final concentrations of 10, 20, 100 ng ml−1,
1 μg ml−1 or 10 μg ml−1. Cells were incubated with VEGF165 and/or Endostatin for
24 hr, after which time the monolayers were washed twice with ice-cold phosphatebuffered saline, and harvested in respective lysis buffers as described.
2.2. FD-70 and FD-4 Permeability Assay
RMEC's were seeded at a cell density of 5×105 cells ml−1 and grown to confluence on
0.1% gelatin coated Costar® Transwell®-Clear inserts (Corning Incorporated, New
York, USA) with a pore size of 0.4 μM. Chambers were examined microscopically
for integrity and uniformity of RMEC monolayers, medium was changed and
VEGF165 or endostatin added at the appropriate concentrations in triplicate inserts for
each time point. Upon reaching confluence, 250 μg ml−1 FD-70 or FD-4 (Sigma
Aldrich, Ireland) (in 400 μl growth medium), was added to the apical chambers of
triplicate control (untreated) monolayers or, those previously exposed to 10 ng ml−1

VEGF165, 20 ng ml−1 endostatin, or a combination of 10 ng ml−1 VEGF165 and
20 ng ml−1 endostatin for 24 hr. RMEC's were placed on a shaker @ 37°C, and at time
‘zero’, 150 μl growth medium was removed from each basolateral chamber, and
replaced with new medium, bringing the basolateral volume to 1.8 ml. Sampling
aliquots were taken every 15 min for 120 min. The fluorescence of FD-70/FD-4 was
determined in a fluorescence spectrofluorometer at an excitation wavelength of
490 nm and an emission wavelength of 515 nm. The apparent permeability coefficient
(Papp) of FD-70/FD-4 was calculated using the following equation:
Papp(cm/s)=dQ/dt×1/A×Co
Where dQ/dt (μg/s) is the rate of appearance of FD-70/FD-4 on the receiver side from
30 to 120 min after application of FD-70/FD-4. Co (μg ml−1) is the initial FD-70/FD-4
concentration on the donor side, and A (cm2) is the effective surface area of the insert.
2.3. Western Blot analysis
2.3.1. Occludin extraction

An occludin-enriched extract was prepared according to the method of Dye et al.
(2001). The cell monolayer was scraped, and homogenised with a 21-gauge needle, in
boiling buffer containing 62.5 mm Tris, 2% SDS, 10 Dithiothreitol, 10 μl protease
inhibitor cocktail/100 ml (Sigma Aldrich, Ireland). The homogenate was centrifuged
at 10 000g for 20 min @ 4°C, and the supernatant was removed for occludin analysis.
2.3.2. ZO-1 extraction

Confluent monolayers of RMECs were scraped and homogenised with a 21-gauge
needle in buffer containing 200 mm HEPES, 1 mm EDTA, 300 mm KCL, 100 mm
MgCl2, 10 (l protease inhibitor cocktail/100 ml. The homogenate was sonicated with
four 5 sec pulses at a frequency of 5.0, and the resulting cell lysate was centrifuged at
500g for 15 min @ 4°C. The supernatant was removed and centrifuged at 40 000g for
2 hr @ 4°C. The resulting supernatant was removed, and the plasma membrane
enriched pellet was re-suspended in buffer containing 6 M Urea, 0.1% Triton X-100,
10 mm Tris, 1 mm Dithiothreitol, 5 mm EGTA, 150 mm NaCl, 10 (l protease
inhibitor cocktail/100 ml (pH 8.0).
Protein concentrations were determined using the Micro-BCA® (Pierce, MSC, Dublin,
Ireland) assay and a BSA standard curve, and equal amounts of protein were loaded
onto SDS-PAGE gels. 10% SDS-PAGE was used for occludin analyses, whilst 6%
SDS-PAGE was used for ZO-1 analyses. Protein samples were separated by
electrophoresis, and transferred to nitrocellulose membrane for 2 hr using a semi-dry
electroblot apparatus. Efficiency of protein transfer was determined using Ponceau-S
solution (Sigma Aldrich, Ireland). Non-specific binding sites were blocked by
incubating the membrane at room temperature with 5% non-fat dry skimmed milk in
TBS (0.05 M Tris, 150 mm NaCl, pH 7.5) for 2 hr. Membranes were briefly washed
with TBS, and incubated with polyclonal rabbit anti-occludin (Zymed, San Francisco,
CA) (1:1000) or polyclonal rabbit anti-ZO-1 (Santa-Cruz Biotech, CA) (1:1000).
Antibodies were incubated with membranes overnight at 4°C. The membranes were
washed with TBS, and incubated with a secondary anti-rabbit (IgG) antibody with a

HRP conjugate (1:2500), for 3 hr at room temperature. Immune complexes were
detected using enhanced chemiluminescence (ECL). After exposure, the X-Ray film
was scanned and densitometric analysis was performed using UVP-Gel Works®.
2.4. Immunoprecipitation analysis
5 μg of rabbit anti-occludin antibody was added to 400 μg of plasma-membrane
enriched fraction of RMEC in Immunoprecipitation (IP) buffer (20 mm Tris, pH 7.5,
150 mm NaCl, 1 mm EDTA, 1 mm EGTA, 1% Triton X-100, 1 mm Na3VO4,
protease inhibitor cocktail), and incubated overnight at 4°C on a roller for mixing.
20 μg Protein-A agarose beads (Sigma Aldrich, Ireland) were added and incubated for
30 min. with agitation at 4°C. Following four washes with 500 μl IP buffer, the
mixture was centrifuged at 14 000g for 2 min at 4°C and supernatant removed. The
pellet was resuspended in 50 μl of 0.1 M Glycine pH 2.5, vortexed and incubated with
agitation for 10 min at 4°C.The mixture was centrifuged at 14 000g, 4°C, for 2 min,
and supernatant removed. 5 μl of 1 M Tris pH 8.0 was added to each tube to neutralise
the pH. 15 μl of 5X concentrated electrophoresis sample buffer (125 mm Tris pH 6.8,
4% SDS, 10% glycerol, 0.006% bromophenol blue, 2% β-mercaptoethanol) was
added to each sample, and boiled for 5 min. The supernatant was loaded onto a 7.5%
SDS-PAGE gel, electrophoresed, transferred was added to nitrocellulose membrane
and probed with rabbit anti-phosphoserine polyclonal antibody, rabbit antiphosphothreoine antibody or rabbit anti-phosphotyrosine antibody (Chemicon,
Temecula, CA), followed by secondary antibody labelled with HRP.
2.4.1. Alakaline-Phosphatase pre-treatment

Lysates of Control (Un-treated), and RMEC's treated for 24 hr with 100 ng ml−1
Endostatin were incubated for 45 min with 50 U ml−1 Alkaline Phosphatase (Sigma
Aldrich, Ireland) at 30°C. (Maik-Rachline et al. (2004)). Lysates were subsequently
immunoprecipitated with rabbit anti-occludin antibody. Following
immunoprecipitation, samples were loaded onto a 7.5% SDS-PAGE gel,
electrophoresed, and transferred to nitrocellulose membrane and probed with rabbit
anti-phosphoserine polyclonal antibody.
2.5. Evan's blue assay for quantitation of inner blood retinal barrier breakdown
in vivo
All studies adhered to the ARVO statement for the use of Animals in Ophthalmic and
Vision Research. C57/Bl6 mice were anaesthetised with gaseous isofluorane, and the
right eye of each of the mice was injected through the sclera, in the region of the
ciliary body, using a 26 g sterile needle (Venisystems Ltd, Abbot Ireland Ltd, Sligo,
Eire).
Animals with a mean weight of 21.24 g were injected as follows: Control Injection
with no growth factor (n=10), 30 ng VEGF (n=10), 60 ng Endostatin (n=10), 30 ng
VEGF+60 ng Endostatin (n=8). The final volume of each injection was 3 μl.
After 24 hr, animals were again anaesthetised with isofluorane, and Evan's blue was
injected intravenously (45 mg kg−1). Upon administration of Evan's blue, mice were

seen to visibly turn blue, and this was used as a confirmation that the dye had been
taken into the bloodstream.
After 3 hr, animals were perfused using citrate buffer at a pressure of 120mmHg for
2 min. and both eyes were removed immediately. Eyes were bisected at the equator,
and retinas were removed under an operating microscope. After determination of the
retinal wet weight, the retinas were completely dried by placing in a Speed Vac
overnight at 60°C. Retinal dry weights were subsequently determined, and retinas
then crushed in 120 μl Formamide at 70°C for 18 hr, in order to remove Evan's blue.
After this time, the extract was centrifuged with a filter centrifuge tube @15 000 rpm
for 30 min. in order to remove retinal debris. The filtrate was subsequently read on the
spectrophotometer at an absorbance of 620 nm, the absorbance maximum for Evan's
Blue, and 740 nm, the absorbance minimum. The concentration of dye in the extracts
was calculated from a standard curve of Evan's blue in formamide. Blood–retinal
barrier breakdown was calculated as previously outlined by Xu et al. (2001).
2.6. Statistical analysis
Statistical analysis of all results obtained was performed using Students t-test, with
results representative of mean and standard deviation and significance represented by
a P-value of ≤0.05. Mean Evan's Blue permeation was graphed with Standard
deviation, and statistics carried out using one-way analysis of variance with a Tukey–
Kramer post-test for multiple comparisons, with P≤0.05 representing significance.

3. Results
3.1. Endostatin inhibits VEGF165 mediated permeability in retinal microvascular
cells in vitro
When VEGF165 (10 ng ml−1) was added to a trans-well insert a significant increase in
the paracellular permeability of RMEC's as determined by FD-70 (Fig. 1A) and FD-4
(Fig. 1B) flux across the monolayer compared to Control (Un-treated) cells(P≤0.05).
Simultaneous treatment of cells with 10 ng ml−1 VEGF165 and 20 ng ml−1 Endostatin,
however, showed a marked decrease in VEGF165 mediated FD-70 flux across the
monolayer, as did initial treatment for 2 hr with 10 ng ml−1 VEGF165 followed by
treatment with 20 ng ml−1 endostatin (P≤0.05) with regards to FD-70 and FD-4 flux
across the monolayer (Fig. 1A and B).

Full-size image (62K)
Fig. 1. Treatment of RMEC's with 10 ng ml−1 VEGF for 24 hr elicited a significant
increase in the apparent permeability coefficient (Papp) across the monolayer of
RMEC's with respect to FD-70 (***P=0.0001) (Fig. 1A). This VEGF mediated
permeability was shown to decrease significantly upon treatment of cells for 24 hr

with 20 ng ml−1 Endostatin (***P=0.0001). RMEC's pre-treated with 20 ng ml−1
Endostatin for 2 hr prior to treatment with 10 ng ml−1 VEGF for 22 hr and cells pretreated for 2 hr with 10 ng ml−1 VEGF and subsequently treated for 22 hr with
20 ng ml−1 Endostatin also showed significant decreases in permeability compared to
10 ng ml−1 VEGF treatment alone. (n=3). (***P=0.0001). 20 ng ml−1 Endostatin was
also shown to significantly decrease the VEGF induced increases in flux of FD-4
across the RMEC monolayer. 10 ng ml−1 VEGF165 pre-treatment for 2 hr followed by
22 hr incubation of cells with 20 ng ml−1 Endostatin elicited a significant decrease in
permeability (*P=0.0449), whilst pre-treatment with 20 ng ml−1 Endostatin for 2 hr
and subsequent treatment for 22 hr with 10 ng ml−1 VEGF165 also decreased VEGF
mediated permeability (*P=0.0229). (n=3). (Fig. 1B).

3.2. Endostatin causes a dose dependent increase in occludin expression
RMEC's exposed to increasing concentrations of Endostatin (10 ng ml−1, 100 ng ml−1,
1 μg ml−1, 10 μg ml−1), showed a dose dependent increase in levels of occludin
expression, which were shown to be significant after densitometric analysis (P≤0.05)
(Fig. 2A and B). Control, untreated, RMEC's showed Occludin migrating as a band of
molecular weight 62 kDa, and a band migrating at approximately 60 kDa. However,
upon treatment of RMEC's with increasing concentrations of Endostatin, the levels of
expression of Occludin were shown to increase 3-fold. Both the 62 kDa, and 60 kDa
forms of occludin were shown to increase. Western blots were normalised with βactin.

Full-size image (41K)
Fig. 2. Control (untreated) RMEC's showed Occludin migrating as a band of
molecular weight 62 kDa, and a band migrating at approximately 60 kDa (Fig. 2A).
However, upon treatment of RMEC's for 24 hr with increasing concentrations of
Endostatin (10 ng ml−1, 100 ng ml−1, 1 μg ml−1 and 10 μg ml−1), the levels of
expression of Occludin were shown to increase in a dose-dependent manner
(100 ng ml−1 Endostatin ***P=0.0002, 1 μg ml−1 Endostatin ***P<0.0001, 10 μg ml−1
Endostatin ***P<0.0001).(Fig. 2B). The 62, and 60 kDa forms of occludin were both
shown to increase. Western blots were normalised using β-actin. (n=3).

3.3. Endostatin causes increased phosphorylation of occludin on serine and
threonine residues
RMEC's serum deprived and treated for 24 hr with 100 ng ml−1 Endostatin showed
increased phosphorylation of Occludin on Serine and Threonine residues, but not

Tyrosine as determined by immunoprecipitation using phospho-specific antibodies
(Fig. 3A). Phosphorylation status of serine residues on occludin was also ascertained
by pre-treatment of cell lysates with 50 U ml−1 Alkaline Phosphatase prior to
immunoprecipitation with rabbit anti-occludin antibody. Phosphorylated serine
residues on occludin (pre-treated with endostatin for 24 hr) were not detected in
alkaline phosphatase-treated samples (Fig. 3B) but were present in samples which had
not been subjected to alkaline phosphatase treatment (Fig. 3B).

Full-size image (48K)
Fig. 3. RMEC's treated with 100 ng ml−1 Endostatin for 24 hr showed an increase in
phosphorylation of occludin on serine and threonine residues compared to the control
(un-treated) cells (Fig. 3A). The large molecular weight band at 62 kD representing
phosphorylated serine residues on occludin was not present in lanes 3 and 4,
corresponding to cell lysates which had been treated for 1 hr with 20 U ml−1 Alkaline
Phosphatase prior to immunoprecipitation with anti-occludin antibody (Fig. 3B),
providing further evidence of specific phosphorylation of occludin in endostatintreated samples (Fig. 3B).

This provides further evidence for increased phosphorylation of occludin in
endostatin-treated RMEC.
3.4. Levels of expression of ZO-1 remain un-changed upon treatment of RMEC's
with VEGF165 or Endostatin
RMEC's treated with 100 ng ml−1 VEGF165 or 100 ng ml−1 Endostatin did not elicit
any significant change in the levels of expression of the tight junction protein ZO-1
after Western blot analysis. This experiment was repeated three times and statistical
analyses of results performed using Student's t-test (Fig. 4A and B).

Full-size image (44K)
Fig. 4. Control (untreated) RMEC's showed the tight junction protein ZO-1 migrating
as a doublet at approximately 220 kDa. This doublet represents the two isoforms ZO1α+ and ZO-1α−. Upon treatment of cells with 100 ng ml−1 VEGF165 for 24 hr, the

levels of ZO-1 expression did not change significantly.(Fig. 4A and B). Treatment of
cells with 100 ng ml−1 Endostatin for 24 hr resulted in no significant change in ZO-1
expression (n=3). Western blot analysis was normalised using β-actin.

3.5. Endostatin antagonises VEGF-mediated retinal vascular permeability in
C57/Bl6 mice
C57/Bl6 mice administered with an intra-ocular injection of 30 ng VEGF165 showed a
significant increase in Evan's blue/albumin permeation at the BRB after 24 hr
compared to un-injected mice and mice administered a control injection with no
solution. This VEGF mediated increase in Evan's blue/albumin permeation at the
BRB was shown to significantly decrease upon administration of a solution
containing 30 ng VEGF +60 ng Endostatin. Mean Evan's Blue/albumin permeation
was graphed with Standard deviation, and statistics carried out using one-way analysis
of variance with a Tukey–Kramer post-test for multiple comparisons, with P≤0.05
representing significance (Fig. 5).

Full-size image (35K)
Fig. 5. Mice injected intra-ocularly through the sclera, in the region of the ciliary body
with 30 ng VEGF165, showed a significant increase in Evan's blue/albumin permeation
at the BRB after 24 hr compared to un-injected mice and mice administered a control
injection with no solution (**P=0.001). Whilst 60 ng Endostatin alone elicited no
significant change in retinal permeability, VEGF165 mediated increases in Evan's
blue/albumin permeation at the BRB was shown to significantly decrease upon
administration of a solution containing 30 ng VEGF +60 ng Endostatin (**P=0.001).
Mean Evan's Blue/albumin permeation was graphed with Standard deviation, and
statistics carried out using one-way analysis of variance with a Tukey–Kramer posttest for multiple comparisons, with P≤0.05 representing significance.

4. Discussion
RMECs at early passage in vitro demonstrate a phenotype that suggests aspects of the
iBRB are maintained in culture (e.g. tight junction expression, low TEER values)
(Tretiach et al., 2003 and Stitt et al., 2000). This makes these cells a reasonable model
system to dissect aspects of the iBRB. Indeed, using endothelial monolayers, several
groups have demonstrated rapid (<30 min) VEGF-mediated increases in permeability
indicating evocation of several pathways including initiation of transcellular gaps,
vesiculovacuolar organelle formation and fenestrations (Bates et al., 1999, Esser et al.,
1998 and Feng et al., 1996). Behzadian et al. (2003), have found a rapid and transient

phase followed by a delayed and sustained phase of VEGF-induced permeability. We
were interested in blood retinal barrier breakdown when the tight junction barrier
breaks and paracellular permeability begins to increase, and we carried out all growth
factor treatments for 24 hr. The current investigation shows that treatment with
VEGF165 for 24 hr increases the permeability between RMEC's with the mechanism
likely to be the paracellular route, as permeability changes due to VEGF have
previously been shown to be accompanied by changes in expression, phosphorylation
and re-distribution of tight junction proteins (Antonetti et al., 1999). We have found
that endostatin, whilst increasing levels of expression, also induced occludin
phosphorylation on serine and threonine residues. Increased phosphorylation of
occludin on specific serine or threonine residues may affect its interactions with ZO1, ZO-2, or ZO-3, which interact with the C-terminal tail of occludin.
We show endostatin reversed the effects of VEGF-enhanced permeability between
RMECs. The effects of endostatin on VEGF mediated permeability, and the increase
in the levels of expression of occludin by endostatin treatment, may serve to regulate
the tight junction at the blood retinal barrier. As a 20 kDa fragment of collagen XVIII,
endostatin is a normal component of the basement membranes that surround the
vascular tubes and acts as a potent angiogenesis inhibitor in the eye (Mori et al.,
2001), possibly acting through a number of cell surface molecules that may serve as
endostatin receptors (Dixelius et al., 2002). Endostatin has been shown to affect
several endothelial cell functions including migration, survival, proteinase activity
and vessel stabilisation (Dixelius et al., 2002). The circulating plasma level of
endostatin in normal human control subjects is 10–50 ng ml−1 (Feldman et al., 2002)
and in the eye it has been shown that vitreous levels of the peptide are higher than
plasma levels in patients with proliferative diabetic retinopathy (Funatsu et al., 2003).
Using physiological levels of endostatin in a relevant in vitro system, the current
study describes the effects of this peptide on retinal microvascular endothelial cell
function. In a model of the BRB, it is evident that this vasoactive peptide can promote
integrity of the retinal endothelial barrier.
In the current investigation we examined physiological levels of endostatin and how
this would affect tight junction integrity and perhaps account for the observed reversal
of VEGF-mediated permeability. Treatment of RMEC's with 1 μg ml−1 of endostatin
induced a two-fold increase in occludin expression. Endostatin induced posttranslational modifications to occludin as seen with increased serine and threonine
phosphorylation (Fig. 3). There are no previous reports of the effects of endostatin on
tight junction expression in the literature, although interestingly the endothelial cell
adherens junctional protein β-catenin is tyrosine phosphorylated in response to acute
treatment with endostatin (Dixelius et al., 2003).
We show that endostatin increases occludin levels after 24 hr treatment, suggesting
that this peptide may regulate capillary permeability through modulation of occludin
at the BRB. Indeed, expression levels of occludin have been shown to correlate with
barrier properties in different tissues (Harhaj and Antonetti, 2004). Endostatin
treatment reversed the VEGF-enhanced permeability, suggesting endostatin may act
to maintain BRB permeability in the event of the VEGF-induced vasopermeability.
The mechanism may involve upregulation in the levels of expression of the tight
junction protein occludin.

Our results on BRB integrity in vivo also show how VEGF165 mediated retinal
permeability can be decreased with physiological levels of endostatin. No statistically
significant differences were found for control, inject-control and endostatin-injected
animals for retinal Evans Blue leakage. Animals injected with VEGF165 showed a
statistically significant increase in retinal Evans Blue leakage (Xu et al., 2001). When
mice were injected with VEGF165 plus endostatin we found a statistically significant
decrease in retinal Evans Blue leakage, compared to VEGF-treated mice, showing
endostatin can reduce VEGF-mediated increases in vascular permeability. Our data
suggest that endostatin could be of therapeutic value in ocular diseases where
increased retinal vasopermeability exists. This is the first report of an antagonistic
effect of endostatin on VEGF-mediated retinal vascular permeability using a
relatively small dose of endostatin (60 ng), and of effects of endostatin on BRB tight
junction proteins. The fact that low levels of endostatin can elicit this effect may be
important when considering therapeutic delivery approaches.
It is significant that endostatin was shown to reverse VEGF-mediated increases in
vasopermeability. Indeed, an in vivo study by Takahashi et al. (2003) showed
intraocular expression of endostatin suppressed leakage of intravascular [3H] mannitol
into the retina. However, it was not possible to determine concentrations of endostatin
that have an effect using this experimental approach. Our data indicate that 20 ng ml−1
of endostatin is sufficient to suppress VEGF-mediated increases in permeability
across RMEC monolayers in vitro whilst 60 ng Endostatin will decrease VEGFmediated permeability in vivo.
VEGF exerts its effect through binding to its two receptor tyrosine kinases, KDR/Flk1 and Flt-1, expressed on endothelial cells. Endostatin blocks VEGF-induced tyrosine
phosphorylation of KDR/Flk-1 and activation of ERK, p38MAPK, and p125FAK,
which are downstream events of KDR/Flk-1 signalling. Several cell surface expressed
molecules, including glypican-1 and -4, may serve as endostatin receptors. Although
endostatin has been shown to bind to the extracellular domains of KDR/Flk-1 and Flt1 resulting in receptor activation being blocked (Kim et al., 2002) it has also been
shown that endostatin does not affect intracellular signalling cascades implicated in
cellular migration and proliferation suggesting endostatin does not directly affect the
VEGF receptor.
Data obtained in the current study suggests endostatin may exert its affect on
vasopermeability by upregulating occludin levels and phosphorylation of occludin on
serine and threonine residues. We are currently determining the specific serine and
threonine residues involved, and the resulting conformational changes. As far as we
are aware, this is the first report of the effects of endostatin on endothelial tight
junction properties and we describe a novel increase in occludin expression and
phosphorylation. This novel effect of endostatin in an in vitro model of the inner
blood retinal barrier function and it's effect on BRB integrity in vivo decrees that this
peptide should be further studied for its potential to prevent clinically significant
retinal vasopermeability changes.
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